← Back to Search

The Effect of Facial Effleurage on Acute Rhinosinusitis

N/A
Waitlist Available
Research Sponsored by Edward Via Virginia College of Osteopathic Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days

Summary

Rhinosinusitis accounts for 12% of the total antibiotic prescriptions filled in the United States annually; however, the majority of rhinosinusitis cases have been proposed to have a viral etiology, or are capable of spontaneously resolving. This overuse of antibiotics is contributing to the development of antibiotic-resistant human pathogenic bacteria, and increasing patient mortality to previously easily cured diseases. This is also causing an unnecessary financial burden especially for uninsured, rural families. Facial Effleurage (FE) is an osteopathic manipulative therapy that allows physicians an alternative therapy to prescribing antibiotics; however, the only scientific literature on the technique is weak in design and execution. This will be a randomized, placebo-controlled clinical trial to test the ability of FE to reduce symptom severity over time, reduce the cellular infiltrate into the nasal cavity, and to more quickly resolve the symptoms of rhinosinusitis compared to antibiotic treatment. This methodical approach to the efficacy of FE has the potential to impact the treatment recommendations of physicians immediately, and to convince more physicians to prescribe less antibiotics and rely more heavily on FE.

Eligible Conditions
  • Sinus Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Symptom Severity

Trial Design

7Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Acute Rhinosinusitis + Facial Effleurage + AntibioticsExperimental Treatment2 Interventions
Sick participants who received the recommended antibiotics and the Facial Effleurage treatment
Group II: Acute Rhinosinusitis + Facial EffleurageExperimental Treatment1 Intervention
Sick participants who received the Facial Effleurage treatment
Group III: Healthy Control + Facial EffleurageActive Control1 Intervention
Healthy participants who received the Facial Effleurage treatment
Group IV: Acute Rhinosinusitis + AntibioticsActive Control1 Intervention
Sick participants who received the recommended antibiotics
Group V: Healthy Control + Sham TreatmentPlacebo Group1 Intervention
Healthy participants who received the sham treatment
Group VI: Acute Rhinosinusitis + Sham TreatmentPlacebo Group1 Intervention
Sick participants who received the sham treatment
Group VII: Acute Rhinosinusitis + Sham Treatment + AntibioticsPlacebo Group2 Interventions
Sick participants who received the recommended antibiotics and the sham treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Antibiotics
2017
Completed Phase 4
~5180

Find a Location

Who is running the clinical trial?

Edward Via Virginia College of Osteopathic MedicineLead Sponsor
20 Previous Clinical Trials
2,347 Total Patients Enrolled
American Osteopathic AssociationOTHER
20 Previous Clinical Trials
3,517 Total Patients Enrolled
~19 spots leftby Dec 2025